SITE009-0055

SITE009 (AUS) › SITE009-0055

SITE009-0055

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2025-11-02

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-11 (study day 243); relationship: not assessed

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-31 (study day 171); relationship: not assessed

mild assessed

Grade 2 Alopecia — outcome: UNKNOWN; onset 2022-10-14 (study day 154); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-07-15 (study day 63); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.